MedTrace Logo

Narrative Exposure Therapy to Reduce Symptoms of Traumatic Stress in Cancer Survivors

NCT05272553 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2022-05-19

No results posted yet for this study

Summary

The main purpose of the study is to evaluate the feasibility, acceptability, and potential effectiveness of NET in reducing symptoms of traumatic stress (e.g., hyperarousal, avoidance, and intrusion) in cancer patients who are not in active treatment.

Further aims include:

* Can NET be effective in reducing symptoms of existential anxiety, anxiety, and depression in cancer patients who are not in active treatment?
* Can NET improve the Quality of Life (QoL) of cancer patients who are not in active treatment? And are improvements in QoL associated to reduction of traumatic stress?
* Can NET lead to post-traumatic growth?
* Does the NET protocol need to be adapted to meet cancer patients' needs?

Conditions

  • Traumatic Stress Disorder
  • Cancer

Interventions

OTHER

Narrative Exposure Therapy

NET (Schauer et al., 2011) is an evidence-based, short-term, manualised treatment for trauma-spectrum disorders; it aims to reduce symptoms of traumatic stress in individuals who continue to suffer from past experiences of traumatic stressors; NET combines principles of CBT, Testimony Therapy, and Exposure Therapy.

Sponsors & Collaborators

  • National Health Service, United Kingdom

    collaborator OTHER_GOV

  • University of Nottingham

    lead OTHER

Principal Investigators

  • Thomas Schröder · The University of Nottingham

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-04
Primary Completion
2023-02-28
Completion
2023-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05272553 on ClinicalTrials.gov